Blood
Articles in this Issue
B-lymphoblastic leukemia with synchronous <i>KMT2A</i> :: <i>TXNRD1</i> and <i>IGH</i> :: <i>CEBPD</i> rearrangements
Novel phosphatase-based regulatory loop for HbF expression
An optimized CRISPR-Cas12a genome-wide screen reveals PTPA phosphatase pathway in fetal hemoglobin silencing
Abstract Reactivating the fetal globin genes HBG1 and HBG2 in adult erythroid cells represents a validated therapeutic approach for hemoglobinopathies. Central mediators of the fet...
How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters tha...
<i>NPM1</i> -mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is a complex hematologic malignancy with multiple disease subgroups defined by somatic mutations and heterogeneous outcomes. Although genome-w...
What next after the first BITE of the CD19 cherry in ALL?
Fueling, then wrecking the megakaryocyte ship
Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21
Abstract ANKRD26-related thrombocytopenia 2 (THC2) is a rare inherited platelet disorder caused by germ line variants in the 5′ untranslated region (UTR) of ANKRD26. Although prior...
Selective depletion of ABO-responsive B cells by T-cell–engaging bispecific antibody conjugates for ABOi transplantation
Abstract Organ transplantation is a pivotal treatment for patients with organ failure. ABO-incompatible (ABOi) transplantation, developed to expand the donor pool, presents signifi...
Common variants, rare disease: new insights into AML risk
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
Abstract VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product, was developed to decrease relapse of high-risk acute myeloid leukemia (AML) or myel...
Beyond the code: noncoding splicing rewires mutant SF3B1
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatum...
Donor T cells on double duty: VCAR33 for AML after transplant
Oncogenic <i>SF3B1</i> mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability
Abstract Oncogenic mutations of SF3B1 are common in myeloid cancers, chronic lymphocytic leukemia (CLL), and select solid tumors. Their mechanistic basis for promoting oncogenesis...
Engineering ABO histocompatibility in transplant and beyond
Carter BZ, Mak PY, Ayoub E, et al. Restoring p53 wild-type conformation in <i>TP53</i> -Y220C–mutant acute myeloid leukemia. <i>Blood</i> . 2025;146(21):2574-2588.
lncRNA and protein team up to drive immune cell identity
The C/EBPα-(PU.1- <i>LOUP</i> ) regulatory circuit regulates monocyte/macrophage development and immune functions
Abstract The myeloid transcription factors PU.1 and CCAAT/enhancer-binding protein α (C/EBPα) are essential for monocyte/macrophage (Mo/MΦ) development, and their dysregulation has...